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Abstract
Background:  Honeybee's sting on human skin can induce ongoing pain, hyperalgesia and
inflammation. Injection of bee venom (BV) into the intraplantar surface of the rat hindpaw induces
an early onset of spontaneous pain followed by a lasting thermal and mechanical hypersensitivity in
the affected paw. The underlying mechanisms of BV-induced thermal and mechanical
hypersensitivity are, however, poorly understood. In the present study, we investigated the role of
mitogen-activated protein kinase (MAPK) in the generation of BV-induced pain hypersensitivity.
Results: We found that BV injection resulted in a quick activation of p38, predominantly in the L4/
L5 spinal dorsal horn ipsilateral to the inflammation from 1 hr to 7 d post-injection. Phosphorylated
p38 (p-p38) was expressed in both neurons and microglia, but not in astrocytes. Intrathecal
administration of the p38 inhibitor, SB203580, prevented BV-induced thermal hypersensitivity from
1 hr to 3 d, but had no effect on mechanical hypersensitivity. Activated ERK1/2 was observed
exclusively in neurons in the L4/L5 dorsal horn from 2 min to 1 d, peaking at 2 min after BV
injection. Intrathecal administration of the MEK inhibitor, U0126, prevented both mechanical and
thermal hypersensitivity from 1 hr to 2 d. p-ERK1/2 and p-p38 were expressed in neurons in
distinct regions of the L4/L5 dorsal horn; p-ERK1/2 was mainly in lamina I, while p-p38 was mainly
in lamina II of the dorsal horn.
Conclusion: The results indicate that differential activation of p38 and ERK1/2 in the dorsal horn
may contribute to the generation and development of BV-induced pain hypersensitivity by different
mechanisms.
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Background
Honeybee's sting on human skin can induce ongoing
pain, hyperalgesia and inflammation. Intraplantar injec-
tion (i.pl.) of bee venom (BV) as an inflammatory pain
model has been widely used [1-3]. Our previous behavio-
ral studies have demonstrated that i.pl. of BV in awake rats
could produce a persistent or tonic spontaneous nocicep-
tion, followed by long-term thermal and mechanical
hyperalgesia, and peripheral inflammation [2,4,5]. BV-
induced peripheral inflammatory symptoms include the
skin becoming red, swollen, hot and aching which are
totally in accordance with the clinical inflammatory
symptoms. Our previous electrophysiological experi-
ments suggest that the BV model possesses many advan-
tages over the formalin test, another inflammatory pain
model, and may be more appropriate to use in the evalu-
ation of the mechanisms underlying clinical pathological
pain [2,6-8].
The mitogen-activated protein kinases (MAPKs) are a fam-
ily of serine/threonine protein kinases, which exist in a
variety of cells. They transduce a broad range of extracel-
lular stimuli into diverse intracellular responses by pro-
ducing changes in transcriptional modulations of key
genes, as well as posttranslational modifications of target
proteins [9,10]. There are four main MAPKs family mem-
bers in mammalian cells: extracellular signal-regulated
kinase1/2 (ERK1/2), p38, c-Jun N-terminal kinase (JNK),
and ERK5, which contribute to different signal transduc-
tion systems [11,12]. Within the past decade, several stud-
ies in rodents have elucidated the roles of ERK, p38, JNK
and ERK5 in generating nociceptive sensitivity and nocic-
eptive plasticity. The activation and the role of MAPKs in
nociceptive plasticity have been extensively studied in the
spinal cord and dorsal root ganglia (DRG). ERK1/2 is acti-
vated during noxious, but not innocuous stimulation
[13,14]. ERK1/2 activation is found in the spinal cord dor-
sal horn under inflammatory pain conditions induced by
complete Freund's adjuvant (CFA) [14], mustard oil [15],
formalin [16,17], or carrageenan [18]. It is believed that
ERK1/2 activation in the spinal cord dorsal horn is
involved in spinal nociceptive processing, neuronal plas-
ticity and central sensitization under inflammatory pain
conditions [12,14,16,19]. p38 can be activated in the spi-
nal cord dorsal horn by intraplantar administration of for-
malin [20,21] or capsaicin [22]. bActivated p38 in the
spinal cord is thought to play an important role in inflam-
mation-induced spinal hyperalgesia [21,23].
It is not clear whether i.pl BV injection induces activation
of MAPK family members in neurons or glial cells in the
spinal cord, and whether their activation contributes to
BV-induced persistent thermal or mechanical hypersensi-
tivity. In the present study, using immunohistochemistry
and behavioral test, we investigated the expression of acti-
vated MAPKs in detail in the spinal cord after i.pl. BV
injection. Further, the functional role of differential acti-
vation of MAPKs in BV-induced peripheral inflammatory
pain in different cells are reported and discussed.
Results
p38 activation in the spinal cord in the BV-inflamed rats
p-p38 immunohistochemistry showed a low constitutive
expression in the L4/5 spinal dorsal horn in naive group
or after saline injection (Fig. 1A, control). The number of
p-p38 labeled cells was slightly increased at 2 min after BV
injection. The number and intensity of p-p38-IR cells
BV injection evoked p38 phosphorylation in rat dorsal horn Figure 1
BV injection evoked p38 phosphorylation in rat dorsal horn. 
(A) p-p38 immunostaining in an L4/5 spinal cord section (16 
μm) in a control and at the indicated time points after intra-
plantar BV injection (200 μg/50 μl). Immunohistochemistry 
shows a gradual increase in the number of p-p38 immunore-
active cells in the ipsilateral spinal cord. (B) Time course of 
BV-evoked p-p38 labeled cells in the lamina I-II of L4/5 dorsal 
horn (n = 4 or 5 each time point, ** p < 0.001; *p < 0.05; 
compared with control; one-way ANOVA). Scale bars, 100 
μm; cont, control.Molecular Pain 2008, 4:17 http://www.molecularpain.com/content/4/1/17
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began to increase more obviously and significantly at 1 hr
and was further increased at 2 hr and 1 d. Three days after
BV injection, the increase in the number and intensity of
p-p38-IR cells peaked in the ipsilateral L4/L5 spinal cord
(Fig. 1A,B). The most prominent increase was found in
laminae I-II of the dorsal horn, but the deep dorsal horn
(laminae III-V) also showed an increase in p-p38-IR cells
(Fig. 1A, 3d).
The total number of p-p38-IR cells in laminae I-II of the
spinal cord was 16.1 ± 1.4 in the control group and 24.0
± 0.9 in the BV group 2 min after injection. There was no
significant difference between the control group and the
BV 2 min group (p = 0.960). The total number of p-p38-
IR cells was significantly increased at 1 hr, 2 hr, 1 d, 2 d
after BV injection and reached a peak at 3 d (Fig. 1B). Then
the number of p-p38-IR cells decreased at 7 d to a level
that was not significantly different from the control group.
These data showed that BV injection significantly induced
p38 activation from 1 hr to 3 d, at which point p38 acti-
vation began to decrease.
In order to identify the cell types which expressed p-p38
in the dorsal horn after BV injection, we performed dou-
ble immunostaining of p-p38 with several cell-specific
markers: NeuN (neuron); GFAP (astrocyte); and Iba1
(microglia). p-p38 immunoreactive cells did not co-
express GFAP (Fig. 2A–C), indicating that p-p38 positive
cells were not astrocytes. The cell types labeled with p-p38
labeled varied; p-p38-IR was partially co-expressed with
NeuN (Fig. 2D–F) and also co-expressed with Iba1 (Fig.
2G–I). The results indicated that p38 was activated in
both neurons and microglia under BV-induced peripheral
inflammation.
BV administration induced a differential activation pat-
tern of p38 in neurons and microglia. The p-p38 labeled
cells mainly co-expressed NeuN at 1 hr or 2 hr after BV
injection (Fig. 3A). The p-p38-IR cells that co-expressed
Iba1, not NeuN, began to increase at 1 d and remained at
a high level until 3 d after BV injection (Fig. 3B). However,
at 7 d the majority p-p38-IR cells were NeuN-IR (data not
shown) and the p-p38 labeled microglia returned to con-
trol level. We counted the number of p-p38-IR neurons
and the number of p-p38-IR microglia in lamina I-II of the
dorsal horn (Fig. 3C). Few microglia expressed p-p38-IR
in the control dorsal horn (2.6 ± 0.3) (Fig. 3C), and the
number of p-p38-IR microglia in the dorsal horn did not
increase significantly from 2 min to 2 hr after BV injection
compared with that of the controls. In contrast, the
number of p-p38-IR neurons increased significantly com-
pared with the controls from 1 hr to 7 d after BV injection
and it peaked at 2 hr (Fig. 3C). The number of p-p38-IR
microglia increased significantly from 1 d to 3 d after BV
injection, and it peaked at 3 d, then decreased to the con-
trol level at 7 d (Fig. 3C).
ERK1/2 activation in the spinal cord in BV-inflamed rats
We next examined whether BV-induced persistent periph-
eral inflammation also induced ERK1/2 activation in the
spinal cord dorsal horn. Few cells expressed p-ERK1/2 in
the spinal dorsal horn of naive or saline-treated rats (Fig.
4A). BV administration induced ERK1/2 activation in the
spinal dorsal horn as early as 2 min after BV injection (Fig.
4B). Activated ERK1/2 was found in the nucleus, cyto-
plasm and dendrites of dorsal horn neurons. The signifi-
cant increase in the number of p-ERK1/2-IR cells was
observed primarily in the superficial dorsal horn ipsilat-
eral to the side of BV injection (Fig. 4B–D). ERK1/2 acti-
vation was not found on the contralateral side (data not
shown). The number of p-ERK1/2-IR cells peaked at 2
min, remained at a high level at 1 hr and decreased over
the next 24 hr after BV injection (Fig. 4B–E). We counted
the number of p-ERK1/2-IR cells in the laminae I-II of the
dorsal horn in control, 2 min, 1 hr, 2 hr, 1 d, and 2 d after
BV injection (Fig. 4E). The number of p-ERK1/2-IR cells
was 0.68 ± 0.3 in controls, and the number of p-ERK1/2-
IR cells significantly increased at 2 min, 1 hr, 2 hr and 1 d
and returned to the control level at 2 d (Fig. 4E).
In order to identify the cell types that expressed p-ERK1/2
in the dorsal horn after BV injection, we performed dou-
ble immunostaining of p-ERK1/2 with cell-specific mark-
ers. The p-ERK1/2 expressing cells did not express GFAP or
Iba1 (data not shown), but all co-expressed NeuN (Fig.
5A–C). We also performed double immunostaining of p-
ERK1/2 with p-p38 to determine whether both MAPKs
were co-expressed after BV injection. The majority of p-
ERK1/2-IR cells were in lamina I, however p-p38 labeled
cells were mainly in lamina II of the spinal dorsal horn. p-
ERK1/2-IR cells did not co-express p-p38-IR (Fig. 5D–F).
Intrathecal administration of a p38 inhibitor, SB203580, 
inhibited BV-induced thermal hypersensitivity, but not 
mechanical hypersensitivity
BV injection into the plantar surface of the hindpaw in the
rat induced both mechanical and thermal hypersensitivity
in the hindpaw from 1 hr to 3 d after BV injection [2],
while in the present study p38 was activated in the dorsal
horn from 1 hr to 7 d after BV injection. To investigate
whether p38 activation has an effect on the development
of mechanical and thermal hypersensitivity after BV injec-
tion, we continuously administered vehicle (10% DMSO)
or SB203580, a specific p38 inhibitor, into the intrathecal
space with a mini-osmotic pump 12 hr before BV injec-
tion and lasting for 3 d. We compared paw withdrawal
latency at different time points after BV injection to the
baseline that was measured before BV injection. Vehicle
treatment had no effect on BV-induced peripheral thermalMolecular Pain 2008, 4:17 http://www.molecularpain.com/content/4/1/17
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and mechanical hypersensitivity (Fig. 6A,B). Intrathecal
administration of SB203580 dose-dependently prevented
BV-induced thermal hypersensitivity. Intrathecal adminis-
tration of 0.5 μg/μl SB 203580 significantly but partially
prolonged paw withdrawal latency from 1 hr to 2 d after
BV injection. A higher dose of SB 203580, 2.5 μg/μl, sig-
nificantly prolonged paw withdrawal latency from 1 hr to
3 d after BV injection (Fig. 6A). The results indicated that
intrathecal administration of 2.5 μg/μl SB 203580 com-
pletely prevented the thermal hypersensitivity induced by
BV injection.
In contrast, intrathecal administration of 0.5 μg/μl or 2.5
μg/μl SB 203580 had no significant effects on mechanical
hypersensitivity after BV injection. The paw withdrawal
threshold was not significant different between the 0.5 μg/
BV induced p38 phosphorylation in both neurons and microglia in the rat L4/5 spinal dorsal horn Figure 2
BV induced p38 phosphorylation in both neurons and microglia in the rat L4/5 spinal dorsal horn. (A-I) Double immunofluores-
cence in the dorsal horn of L4/5 spinal cord sections (16 μm) at 3 d after BV-injection, for p-p38 (green) and GFAP, an astro-
cyte marker (red; B, C); NeuN, a neuronal marker (red; E, F); and Iba1, a microglia marker (red; H, I) (40×). (A-C) p-p38-IR 
was not co-expressed with GFAP-IR. (D-F) Double immunofluorescence for p-p38 and NeuN indicated partial colocalization of 
p-p38 and NeuN (F, white arrow). There were many p-p38-IR cells that are not co-expressed with NeuN in the dorsal horn 
after BV injection (F, white arrow head). (G-I) p-p38-IR which is not co-expressed with NeuN colocalized with Iba1 (I, white 
arrow head). Scale bars, 50 μm (A-I).Molecular Pain 2008, 4:17 http://www.molecularpain.com/content/4/1/17
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μl SB 203580, 2.5 μg/μl SB203580 and vehicle groups
(Fig. 6B).
Intrathecal administration of the MEK inhibitor, U0126, 
inhibited both BV-induced thermal and mechanical 
hypersensitivity
To examine the functional role of ERK1/2 activation in
BV-induced inflammatory pain, we continuously admin-
istered vehicle (10% DMSO) or 1 μg/μl U0126, a potent
and selective MEK inhibitor, which was dissolved in 10%
DMSO, into the intrathecal space with a mini-osmotic
pump (1 μl per hour) 12 hr before BV injection and last-
ing for 3 d. Intrathecal U0126 and vehicle administration
had no effect on basal thermal and mechanical behavior.
The U0126 dose used was in accordance with previous
work. Vehicle treatment had no obvious effect on BV-
induced peripheral thermal and mechanical hypersensi-
tivity (Fig. 6C,D).
Intrathecal administration of U0126 significantly, but not
completely, prevented BV-induced thermal hypersensitiv-
ity. Intrathecal administration of 1 μg/μl U0126 signifi-
cantly prevented the paw withdrawal latencies compared
with vehicle level from 1 hr to 2 d after BV injection (Fig.
6C). For mechanical hyperalgesia, the intrathecal admin-
istration of 1 μg/μl U0126 significantly and completely
prevented the mechanical hyperalgesia induced by BV
injection (Fig. 6D). The paw withdrawal thresholds at dif-
ferent time points were not significantly different after
U0126 treatment (Fig. 6D). The results indicated that
intrathecal administration of 1 μg/μl U0126 completely
BV induced different activation patterns of p38 in neurons and microglia in the L4/5 rat spinal dorsal horn Figure 3
BV induced different activation patterns of p38 in neurons and microglia in the L4/5 rat spinal dorsal horn. (A-B) Double 
immunofluorescence in the dorsal horn of L4/5 spinal cord sections (16 μm) for p-p38 (green) and NeuN, a neuronal marker 
(red) at 2 h and 4 d after BV injection (10×). (C) Time course showing the number of p-p38-IR neurons and microglia in the I-
II laminae in L4/5 dorsal horn. Double immunofluorescence and histograms show that p38 was activated in neurons as early as 
1 hr and peaked at 2 hr; while p38 was activated in microglia at 1 d and peaked at 3 d after BV administration. (n = 4 or 5 each 
time point, ** p < 0.001; *p < 0.05; compared with controls; one-way AVOVA). Scale bars, 100 μm (A, B). cont, control.Molecular Pain 2008, 4:17 http://www.molecularpain.com/content/4/1/17
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prevented mechanical hyperalgesia, but only partly pre-
vented thermal hypersensitivity induced by BV injection.
Discussion
In this study, we investigated the activation and func-
tional role of the MAPKs family (ERK1/2, p38) in the spi-
nal cord in the BV-induced inflammatory pain model
[2,24]. The present findings are comprised of four key
observations: (1) BV injection induced persistent p38 acti-
vation in both spinal neurons and microglia. The activa-
tion of p38 in neurons occurred from 1 hr, while in
microglia it started from 1 d after BV injection. (2) Intrath-
ecal administration of the p38 inhibitor, SB203580, pre-
vented thermal but not mechanical hyperalgesia induced
by BV from 1 hr to 3 d. (3) BV injection induced ERK1/2
activation in spinal neurons from 2 min to 1 d, but not
throughout the time course of activation observed in
microglia. (4) Inhibition of ERK1/2 activation by the MEK
inhibitor, U0126, prevented both thermal and mechani-
cal hyperalgesia induced by BV from 1 hr to 2 d.
BV induced p38-activation in the spinal dorsal horn
p38, a member of the MAPK family, is activated by cellu-
lar stress and inflammatory cytokines [11]. In the present
study, we found that p38 was activated in both spinal neu-
rons and microglia after BV injection into the plantar sur-
face of the hindpaw. The number of p-p38 expressing cells
was significantly increased from 1 hr to 7 d in the ipsilat-
eral L4/5 spinal cord and peaked at 3 d (Fig 1). Intra-
plantar injection of BV induced tonic spontaneous
nociceptive responses (flinching or licking and lifting of
the injected paw) immediately and lasting for about 1 hr
after injection and then was followed by long-term hyper-
algesia. The number of p-p38-IR cells was not significantly
increased at 2 min after BV injection, which indicates that
p38 may not contribute to the onset of spontaneous pain.
Our behavioral data showed BV-induced thermal and
mechanical hyperalgesia was maintained from 1 hr to 3 d
after BV-injection (Fig. 6, vehicle). The time courses of
pain behavior and p-p38 expression coincided well with
each other, suggesting a potential role of p38 activation in
BV-induced pain hypersensitivity.
Interestingly, pretreatment with the p38 inhibitor dose-
dependently inhibited the thermal hyperalgesia, but did
not have any effect on the BV-induced mechanical hyper-
algesia. These data suggest that p38 activation may play an
important role in BV-induced thermal hyperalgesia, but
not mechanical allodynia. Several lines of evidence have
demonstrated that activation of p38 in the spinal cord is
involved with the thermal hypersensitivity from periph-
eral inflammation induced by CFA, formalin or carra-
geenan [21,25]. p38 activation in the spinal cord is
thought to be necessary for thermal hyperalgesia forma-
tion, therefore intrathecal administration of p-p38 inhib-
itors may inhibit the effect of activated p38 and the
formation of thermal hyperalgesia [26,27]. In addition to
the role of p38 in inflammatory pain, it has been reported
that activation of p38 is induced by peripheral nerve
injury. Administration of p38 inhibitors can block both
thermal hyperalgesia [28,29] and mechanical allodynia
[28,30,31] following peripheral nerve injury. Therefore, it
ERK was phosphorylated in the rat L4/5 spinal dorsal horn  after BV injection Figure 4
ERK was phosphorylated in the rat L4/5 spinal dorsal horn 
after BV injection. (A) Control p-ERK immunostaining in an 
L4/5 spinal cord section (16 μm) after intraplantar saline 
injection (50 μl). Only a few of p-ERK-IR cells were detected. 
(B-D) p-ERK immunostaining in L4/5 spinal cord sections (16 
μm) at 2 min, 2 hr, and 2 d after intraplantar BV injection 
(200 μg/50 μl). p-ERK-IR cells were distributed mainly in lam-
inae I-II of the spinal dorsal horn. Immunohistochemistry 
indicates a rapid increase in the number of p-ERK immunore-
active cells in the ipsilateral spinal cord at 2 min. (E) Time 
course of BV-evoked p-ERK labeled cells in the L4/5 dorsal 
horn. (n = 4 or 5 each time point, ** p < 0.001; *p < 0.05; 
compared with controls; one-way AVOVA). Scale bars, 50 
μm in A-D. cont, control.Molecular Pain 2008, 4:17 http://www.molecularpain.com/content/4/1/17
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seems likely that p-p38 is only involved in thermal hyper-
algesia in inflammatory pain models, but is involved in
both thermal and mechanical hyperalgesia in neuropathic
pain models. Thus, p-p38 may play different roles under
inflammatory and neuropathic pain conditions.
Double immunostaining of p-p38 with several cell-spe-
cific markers indicated that p-p38 was expressed in both
neurons and microglia; the number of p-p38-IR neurons
was significantly increased from 1 hr after BV injection
and was maintained at a high level until 7 d. The number
of p-p38-IR microglia was significantly increased from 1 d
and peaked at 3 d after BV injection and then decreased to
control level (Fig. 3). Our behavior data indicated that
both thermal and mechanical hyperalgesia were induced
from 1 hr and peaked within 3 d. However, activation of
p38 in neurons continued for at least 7 d (Fig. 3). These
data suggested that activation of p38 in neurons may be
important to the induction, but not the maintenance, of
BV-induced thermal hyperalgesia. Activation of p38 in
microglia was induced from 1 d and peaked at 3 d, then
returned to baseline by 7 d, which was completely consist-
ent with the time course of thermal hyperalgesia. Thus,
instead of a role in neurons, activation of p38 in microglia
may contribute to the maintenance of BV-induced ther-
mal hyperalgesia. It has been reported that p38 activation
is induced in spinal microglia by CFA [21], carrageenan
[25], or formalin intraplantar injection [19,32-34]. It is
believed that p38 activation in microglia can worsen the
inflammatory process by releasing proinflammatory
mediators, which exert effects on neurons and contributes
to pain hypersensitivity [35].
BV-induced ERK1/2 activation in the spinal dorsal horn
Peripheral or central ERK pathways have been found to
contribute to pain hypersensitivity in inflammatory and
neuropathic pain models [13,14,16,36,37]. ERK activa-
tion in spinal dorsal horn neurons contributes to central
sensitization through post-translational regulation
processing at early times [14], and through transcriptional
mechanisms at later times which leads to inflammatory
pain hypersensitivity [19]. In the present study, we found
that ERK1/2 was activated within 2 min in ipsilateral spi-
nal neurons of lamina I-II, and maintained for as long as
BV induced ERK phosphorylation only in neurons that did not co-express p-p38 in the rat L4/5 spinal dorsal horn Figure 5
BV induced ERK phosphorylation only in neurons that did not co-express p-p38 in the rat L4/5 spinal dorsal horn. (A-C) Dou-
ble immunofluorescence in spinal dorsal horn sections (16 μm) for p-ERK (green) and NeuN, a neuronal marker (red). Double 
immunofluorescence indicated significant colocalization between p-ERK and NeuN. (D-F) Double immunofluorescence in the 
dorsal horn of an L4/L5 spinal cord section (16 μm) for p-ERK (green) and p-p38 (red). Double immunofluorescence indicated 
p-ERK and p-p38 did not colocalize. Scale bars, 50 μm (A-F).Molecular Pain 2008, 4:17 http://www.molecularpain.com/content/4/1/17
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24 hr after BV-injection. The rapid activation of ERK1/2 in
the spinal cord may involve BV-induced tonic spontane-
ous nociceptive responses. In contrast to the expression of
p-p38, p-ERK1/2 was induced exclusively in neurons. We
found that p-ERK1/2 was not co-expressed with p-p38 in
neurons in the dorsal horn after BV-injection. These data
suggested that ERK1/2 and p38 were activated in separate
cells following BV injection, and may contribute to neuro-
nal hypersensitivity by different mechanisms. Indeed, pre-
treatment with the MEK inhibitor significantly prevented
both thermal and mechanical hyperalgesia induced by BV
injection, while the p38 inhibitor just inhibited the ther-
mal hyperalgesia (Fig. 6).
ERK1/2 activation was found in the spinal cord following
formalin, carrageenan or CFA intraplantar injection
[14,18,19,38]. Formalin- or carrageenan-induced ERK
activation is rapid and can be maintained for as long as 60
min [14,18], while CFA-induced ERK activation can per-
sist in the spinal dorsal horn for about 48 hr [19], or even
as long as 7 d [38]. We found that ERK1/2 was activated
from 2 min and maintained as long as 24 hr in the ipsilat-
eral spinal dorsal horn after BV injection. The temporal
Effects of pre-administration of SB203580 or U0126 on the induction and maintenance of BV-induced thermal and mechanical  hypersensitivity Figure 6
Effects of pre-administration of SB203580 or U0126 on the induction and maintenance of BV-induced thermal and mechanical 
hypersensitivity. The paw withdrawal latencies or thresholds at different time points after BV injection are presented as the 
ratio compared with the baseline. (n = 6 or 5 each time point, ** p < 0.001; *p < 0.05; compared with vehicle; t-test #: p < 0.05; 
compared with baseline, AVOVA). BL, baseline.Molecular Pain 2008, 4:17 http://www.molecularpain.com/content/4/1/17
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pattern in our results differs from the above-mentioned
studies and this difference may be due to the differences
in the employed animal models.
In the present study, using immunohistochemistry and
behavioral tests, we investigated the expression and func-
tional role of activated p38 or ERK1/2 in the spinal cord
after i.pl. BV. Our data show that intraplantar BV-injection
can cause activation of ERK1/2 only in neurons in the spi-
nal dorsal horn, and cause activation of p38 in both spinal
neurons and microglia. Intrathecal administration of a
MEK inhibitor significantly prevented the BV-induced
thermal and mechanical hyperalgesia, while the p38
inhibitor prevented thermal hyperalgesia but had no
effect on mechanical hyperalgesia. In conclusion, activa-
tion of ERK1/2 may contribute to BV-induced spontane-
ous pain and both thermal and mechanical hyperalgesia.
Activation of p38 in spinal neurons may be important for
the generation of BV-induced thermal hyperalgesia and in
microglia may be involved in the maintenance of BV-
induced thermal hyperalgesia.
Methods
Animals and bee venom administration
The experiments were performed on male Sprague-Daw-
ley albino rats weighted 250–300 g. The animals were
kept 2–4 per cage under a 12 h/12 h light-dark cycle
regime at room temperature (23–24°C), with free access
to food and water. All animal experimental procedures
were approved by the Hyogo College of Medicine Com-
mittee on Animal Research and were performed in accord-
ance with the college's guidelines for the care and use of
laboratory animals.
A volume of 50 μl (200 μg) BV solution (crude venom of
honey bee, Sigma-Aldrich Inc, St Louis, U.S.A.) dissolved
in 0.9% sterile saline was used. Subcutaneous injection of
BV was administered into the posterior plantar surface of
the hindpaw of rats under ether anesthesia as reported
previously [2].
Implantation of intrathecal catheters and administration 
of inhibitors
For chronic and continuous intrathecal drug administra-
tion, rats were implanted with catheters as described pre-
viously [36,39,40]. In brief, under anesthesia with sodium
pentobarbital (40 mg/kg, i.p.), an L5 vertebrae laminec-
tomy was performed, and a soft tube (Silascon, Kaneka
Medix Company, Osaka, Japan; outer diameter, 0.64 mm)
was inserted into the subarachnoid space of the spinal
cord and advanced 3 cm rostrally to the level of the lum-
bar enlargement (the L4/L5 level) via an incision in the
dura. Then the muscle incision was sutured and a small
subcutaneous pocket was made by spreading apart the
subcutaneous connective tissue behind the incision. Next,
an Alzet mini-osmotic pump (Model 1003D, CA, U.S.A.
providing 72 h of drug delivery) filled with a p-p38 inhib-
itor, 4-(4-fluorophenyl)-2-4-methylsulfonyl-phenyl)-5-
(4-pyridyl)-1H-imidazole (SB203580, Calbiochem, La
Jolla, CA, U.S.A., in 10% dimethylsulphoxide (DMSO))
or a potent and specific MEK inhibitor, 1,4-Diamino-2,3-
dicyano-1,4-bis (2-aminophenylthio) butadiene (U0126,
1  μg/μl in 10% DMSO) (Calbiochem, La Jolla, CA,
U.S.A.), or vehicle (10% DMSO) was put into the pocket
and connected to the tube. The pump was soaked in sterile
saline overnight prior to pump implantation. The rats
were housed individually after surgery and only those
without motor disturbance and other neurological deficits
were included for further experiments. Two doses of
SB203580 (0.5, 2.5 μg/μl) dissolved in 10% DMSO were
used. The doses of these inhibitors were determined on
the basis of our preliminary experiments [41,42].
Immunohistochemistry
At appropriate times, control and BV-inflamed rats were
deeply anesthetized with sodium pentobarbital (50 mg/
kg, i.p.) and then perfused through the ascending aorta
with 1% paraformaldehyde in 0.1 M phosphate-buffer
(PB, pH 7.4), followed by 4% paraformaldehyde in 0.1 M
PB. After perfusion, the L4/L5 spinal cords were removed
and postfixed in the same 4% fixative overnight at 4°C
and dehydrated by immersion in 20% sucrose in 0.1 M PB
at 4°C overnight. The tissue was embedded with Tissue-
Tek (Sakura Finetek, Co Ltd, U.S.A.) and frozen in dry ice
powder. Transverse sections were cut into 16 μm thick sec-
tions at -28 °C in a cryostat.
The sections were processed for immunohistochemistry
using the ABC method according to the floating proce-
dure. Sections were blocked with 10% normal goat serum
in 0.1 M PBS (pH 7.4) for 1 hr at RT and incubated with
one of the following primary antibodies: anti-p-p38 anti-
body (rabbit anti phospho-p38, Thr180/Tyr 182; 1:400;
Cell Signaling Technology, U.S.A.) or anti-p-ERK1/2 (rab-
bit anti phospho-p44/42 MAP kinase; 1:1000; Cell Signal-
ing Technology, U.S.A.), over two nights at 4°C. The
sections were then incubated overnight at 4°C with bioti-
nylated secondary antibody (goat anti rabbit, 1:400; Vec-
tor, Germany).
For double immunofluorescence, sections were incubated
with a mixture of rabbit anti-p-p38/p-ERK1/2 antiserum
and mouse monoclonal anti-neuronal specific nuclear
protein (NeuN) (neuronal marker, 1:2000; Chemicon,
Temecula, CA) or mouse monoclonal anti-glial fibrillary
acidic protein (GFAP) antiserum (astrocyte marker,
1:2000; Chemicon, MA, U.S.A.) over two nights at 4°C,
followed by a mixture of Alexa Fluor 488 or Alexa Fluor
594 fluorescence conjugated secondary antibodies (1:
1000; Molecular Probes, OR, U.S.A.) overnight at 4°C.Molecular Pain 2008, 4:17 http://www.molecularpain.com/content/4/1/17
Page 10 of 11
(page number not for citation purposes)
The double-stained images were examined with an Axio-
vert/LSM510 confocal scanning microscope (Carl Zeiss
Microimaging, Inc., Germany). The tyramide signal
amplification (TSA Indirect Method, Product NEL 700A,
PerkinElmer Life Sciences, Boston, MA) fluorescence pro-
cedures [36] were used for double immunofluorescent
staining p-p38/p-ERK1/2 with ionized calcium binding
adaptor molecule 1 (Iba1, microglia marker, 1:1000;
Wako, Tokyo, Japan).
Behavioral test
We detected both thermal and mechanical hyperalgesia in
the injected paw before or at 1 hr, 2 hr, 3 hr, 5 hr, 8 hr, 1
d, 2 d, 3 d and 5 d after BV injection. Mechanical hyperal-
gesia was assessed with an automated von Frey-type sys-
tem [43,44], the dynamic plantar aesthesiometer (Ugo
Basile, Comerio, Italy). To measure rat hindpaw mechan-
ical thresholds, rats were placed in plastic cages with a
wire mesh floor and allowed to acclimate for 2 hr before
each test session. A paw-flick response was elicited by
applying an increasing force (measured in grams) using a
plastic filament (0.5 mm diameter) focused on the plantar
surface of the ipsilateral hindpaw. The force applied was
initially below detection threshold and then gradually
increased from 1 to 50 g over 20 s, then held at 50 g for a
further 10 s. The rate of force increase was 2.5 g/s. The
force applied to elicit a reflex removal of the ipsilateral
hindpaw was considered to be the threshold of mechani-
cal pain. At least three measurements at 5 min intervals
were taken at each time-point and the mean of three
measurements was considered the paw withdrawal
threshold.
To examine thermal hyperalgesia, the rats were placed in
a plastic chamber on the surface of a 2 mm thick glass
sheet and a radiant heat stimulus from the Plantar Test
(7370 Ugo Basile, Italy) was applied to the injection site
of the hindpaw. The heat stimulus was terminated with a
withdrawal response, or at 20 s to avoid skin damage. The
paw withdrawal latency was defined as the duration from
the beginning of heat stimuli to the occurrence of the
hindpaw withdrawal reflex. Three stimuli were repeated
for each site and paw withdrawal thermal latency was
obtained by obtaining the mean. The inter-stimulus inter-
val for each heat test at the same region was 5 min.
Quantitative and statistical analysis
To obtain the number of the immunoreactive cells in the
spinal cord sections, 5 sections were randomly selected
from each rat, and the mean number from these 5 sections
was considered the number of immunoreactive cells per
section/rat. The number of immunoreactive cells in the
spinal dorsal horn was counted from laminae I-II of spinal
cord.
Data were expressed as mean ± S.E.M. Differences in
changes of values over time of each group were tested
using T-tests and one-way or two-way repeated ANOVA,
followed by individual post-hoc comparisons (Turkey test).
A difference was accepted as significant if p < 0.05.
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